Table 1.
Clinical characteristics of cirrhotic patients infected with SARS-CoV-2
|
Reference
|
Patientnumber (n)
|
Region
|
Etiology
|
CirrhosisSeverity1
|
ACLF2
|
Acute decompensation
|
| Qi et al[33] | 21 | China | HCV: 9.5% | CTP-A: 76.2% | 4.8%3 | Variceal bleeding: 19% |
| HBV: 42.9% | CTP-B: 14.3% | |||||
| ALD: 9.5% | CTP-C: 9.5% | Ascites: 23.8% | ||||
| AIH: 4.8% | MELD: 8 (7-11) | |||||
| Liu et al[32] | 17 | China | HCV: 11.8% | CTP-A: 88.2% | APASL:11.8% | Variceal bleeding: 5.9% |
| HBV: 70.6% | CTP-B: 5.9% | |||||
| CTP-C: 5.9% | ||||||
| Iavarone et al[31] | 50 | Italy | HCV: 28% | CTP-A: 40% | EASL: 28% | HE: 22% |
| HBV: 10% | CTP-B: 28% | |||||
| ALD: 24% | CTP-C: 32% | |||||
| NAFLD: 6% | MELD: 9 (6-15) | |||||
| Sarin et al[14] | 43 | Asia | Viral: 60.4% | CTP-A: 53.8% | APASL: 11.6% | AD event: 9.3% |
| MAFLD: 32.5% | CTP-B: 37.2% | Variceal bleeding: 9.3% | ||||
| ALD: 4.6% | CTP-C: 9% | HE: 7% | ||||
| AIH: 2.3% | Ascites: 23.3% | |||||
| Jaundice: 23.3% | ||||||
| SBP: 7% | ||||||
| Moon et al[19] | 103 | International | HCV: 10.5% | CTP-A: 44.7% | N/A | AD event: 25.7% |
| HBV: 11.8% | CTP-B: 29.1% | Variceal bleeding: 1% | ||||
| ALD: 19.7% | CTP-C: 26.2% | HE: 16.5% | ||||
| NAFLD: 22.4% | MELD: 10 | Ascites: 27.2% | ||||
| SBP: 2.9% | ||||||
| Lee et al[22] | 14 | Korea | HCV: 14.3% | CTP-A: 64.3% | N/A | Secondary infection: 7.1% |
| HBV: 35.7% | CTP-B: 35.7% | |||||
| ALD: 35.7% | MELD: 8 (7-12) | |||||
| AIH: 7.1% | ||||||
| Bajaj et al[23] | 37 | United States | HCV: 24.3% | MELD: 17.6 ± 8.6 | NACSELD: 30% | Variceal bleeding: 14% |
| ALD: 24.3% | ||||||
| HE: 14% | ||||||
| NASH: 24.3% | ||||||
| Kimet al[21] | 227 | United States | N/A | Compensated: 59% | N/A | AD event: 29.5% |
| Variceal bleeding: 3.1% | ||||||
| Decompensated: 41% | ||||||
| HE: 10.1% | ||||||
| Ascites: 4.8% | ||||||
| Shalimar et al[30] | 26 | India | HCV: 7.7% | CTP: 8.6 ± 2.3 | EASL: 34.6% | AD event: 61.5% |
| HBV: 11.5% | MELD: 18.1 ± 9.6 | Variceal bleeding: 30.8% | ||||
| ALD: 34.6% | Ascites: 7.7% | |||||
| NAFLD: 7.7% | ||||||
| AIH: 15.4% | ||||||
| Marjot et al[18] | 386 | International | HCV: 11% | CTP-A: 52% | EASL: 23% | AD event: 46% |
| HBV: 21% | CTP-B: 30% | Variceal bleeding: 3% | ||||
| ALD: 38% | CTP-C: 17% | HE: 27% | ||||
| NAFLD: 26% | MELD: 12 (8-19) | Ascites: 28% | ||||
| SBP: 3% | ||||||
| Jeon et al[28] | 67 | Korea | N/A | N/A | N/A | Variceal bleeding: 3% |
| Ascites: 3% | ||||||
| HE: 4.5% |
Cirrhosis severity based on Child-Turcotte-Pugh classification and model for end-stage liver disease score.
Definition of acute-on-chronic liver failure (ACLF) based on the The North American Consortium for the Study of End-Stage Liver Disease, Asian Pacific Association for the Study of the Liver, and The European Association for the Study of the Liver guidelines.
Definition of ACLF was not mentioned in the study.
ACLF: Acute-on-chronic liver failure; AD: Acute decompensation; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ALD: Alcohol-related liver disease; AIH: Autoimmune hepatitis; CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; APASL: Asian Pacific Association for the Study of the Liver; NAFLD: Nonalcoholic fatty liver disease; EASL: The European Association for the Study of the Liver; SBP: Spontaneous bacterial peritonitis; HE: Hepatic encephalopathy; MAFLD: Metabolic-associated fatty liver disease; NASH: Nonalcoholic steatohepatitis; NACSELD: The North American Consortium for the Study of End-Stage Liver Disease